Carbamic Acid

Carbamic Acid

SCHEMBL7781024

CCC1CCCC1.NC(=O)O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.45
CYP2D6 P10635 1/20 0.39
EPHX1 P07099 3/20 0.38
SLC1A3 P43003 3/20 0.37
SLC1A2 P43004 3/20 0.37
SLC1A1 P43005 3/20 0.37
CYP1A2 P05177 1/20 0.36
LMNA P02545 1/20 0.35
PARP15 Q460N3 1/20 0.35
PARP10 Q53GL7 1/20 0.35
ACHE P22303 1/20 0.35
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Urea SCHEMBL1835314 0.92 ALOX5 (0.46) ALOX5CYP2D6EPHX1CYP1A2PARP15
Urea SCHEMBL11805177 0.90 ALOX5 (0.48) ALOX5CYP2D6EPHX1CYP1A2
Urea SCHEMBL1837609 0.90 ALOX5 (0.48) ALOX5CYP2D6EPHX1CYP1A2
Bicarbonate SCHEMBL10453278 0.90 CYP1A2 (0.39) ALOX5CYP2D6EPHX1SLC1A3SLC1A2
Acetic Acid SCHEMBL27585871 0.87 CYP1A2 (0.37) ALOX5CYP2D6EPHX1SLC1A3SLC1A2
Bicarbonate SCHEMBL6470832 0.87 CYP1A2 (0.42) ALOX5CYP2D6EPHX1CYP1A2LMNA
Cyclohexane SCHEMBL28777359 0.85 CYP1A2 (0.41) ALOX5CYP2D6EPHX1SLC1A3SLC1A2
Propionic Acid SCHEMBL19813178 0.85 FFAR3 (0.50) ALOX5CYP2D6EPHX1CYP1A2LMNA
Acetic Acid SCHEMBL2485175 0.85 CYP1A2 (0.41) ALOX5CYP2D6EPHX1SLC1A3SLC1A2
Bicarbonate SCHEMBL2862271 0.84 ALOX5 (0.38) ALOX5CYP2D6EPHX1SLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1133293-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2001-09-19 EP disclosed
WO-2000030639-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2000-06-02 WO disclosed